Navigation Links
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
Date:12/9/2008

Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings

PRINCETON, N.J., Dec. 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that a Phase 1 dose escalating study of CPX-351 (cytarabine:daunorubicin) Liposome Injection established the recommended dose for Phase 2 studies and confirmed preliminary observations of safety, enhanced pharmacokinetics and promising anti-tumor activity in patients with advanced leukemia. A final analysis of the Phase 1 data (abstract #2984) and supportive findings from a pre-clinical pharmacodynamic model (abstract #942) were presented at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco.

"In the Phase 1 trial, CPX-351 had a tolerability profile that appears better than conventional cytarabine/daunorubicin treatment and produced impressive anti-leukemic responses, including complete remissions (CRs) at and below the maximum tolerated dose, in relapsed and refractory patients," said Eric J. Feldman, MD, of the Weill Medical College of Cornell University and New York-Presbyterian Hospital, the principal investigator in the study. "These encouraging results suggest that CPX-351 may offer advantages to conventional administration of these commonly used drugs. We are excited to participate in the two Phase 2 studies."

In the study, complete remissions were observed in 11 of 47 patients, including 10 patients (9 CRs and 1 CRp - complete remission without full platelet recovery) of 44 with AML and 1 patient of 3 with acute lymphocytic leukemia (ALL) following treatment with CPX-351. Of the 10 AML CRs, 7 occurred at the two highest dose levels, although complete remissions were achieved at dose levels as little as one third of the maximum tolerated dose (MTD). Of note, 7 CRs were achieved in 22 patient
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
5. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
6. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
7. Memory Pharmaceuticals Receives NASDAQ Decisions
8. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... released a new blog post explaining how to find ... find low cost auto insurance is by comparing quotes. Drivers ... a simple and convenient way. It is no longer necessary ... All the details are now freely available to anyone on ... to compare online car insurance quotes on a single website. ...
(Date:4/26/2015)... 2015 A live auction will be ... from hospitals, surgery centers and other medical facilities around ... sold including radiology, surgery, endoscopy, lab, anesthesia, exam and ... place Tuesday, April 28th starting at 10:00am EDT. The ... 5025 North Hiatus Rd., Sunrise, FL 33351. Anyone ...
(Date:4/26/2015)... 2015 Forbes Living is scheduled ... one which is synonymous with clean beaches, sparkling office buildings, ... are major economic influencers in the city on the Pacific ... show are pleased to announce the show will be broadcast ... 3:00 PM PDT. Tune in to find out what the ...
(Date:4/25/2015)... 26, 2015 Diversified Communications has ... healthcare event. The Integrative Healthcare Symposium Canada, as ... 2015 at the Sheraton Parkway Toronto North in ... one of the most anticipated events of the ... CME program. The event aims to gather multi-disciplined ...
(Date:4/25/2015)... In the United States alone, an ... treatment for an illicit drug or alcohol ... Mental Health Services Administration’s Survey on Drug Use and ... are harrowing stories of men and women whose lives ... David H. Kerr , founder and retired president of ...
Breaking Medicine News(10 mins):Health News:Finding Low Cost Auto Insurance - An Online Guide Provides Tips 2Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Forbes Living TV Will Air in San Diego, California 2Health News:Integrative Healthcare Event launching in Canada 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3
... Michael Fenech studied the damage of excess alcohol on human DNA. ... of // alcoholic beverages resulted in increased risk of permanent damage ... six men aged 21-26 stuck to a diet low in plant ... complete red wine, red wine with the alcohol removed or alcohol ...
... the University of Washington researchers between obesity and asthma. ... the Journal of Allergy and Clinical Immunology. Previous studies ... develop asthma. The new research reveals the common genetic ... ,The researchers led by Dr. Teal Hallstrand analyzed ...
... were infected with the H5N1 bird flu died in spite ... The virus appears to have developed a resistance // to ... The virus was seen to mutate in the patients, becoming ... were seen in both cases. ,This has ...
... human cancer cells in a unique way will be ... Zealand. The clinical trial would be held at New ... on Wednesday. ,Auckland University cancer researcher Professor Bill ... is converted to a DNA damaging agent in the ...
... consistent with the Christmas season says that a serving or ... prevent heart disease. ,This comes as a breath of ... of the study were researchers at Zurich's University hospital. They ... chocolate with a relatively high cocoa content (75 per cent) ...
... US federal health agents have launched an inquiry into the ... of the product has been stopped at the California and ... test reportedly gives a result in just 20 minutes. The ... for, in addition to its speed. ( ...
Cached Medicine News:
(Date:4/24/2015)... -- Perrigo Company plc ("Perrigo" or the "Company") (NYSE: PRGO, ... from Mylan NV ("Mylan") (NASDAQ: MYL ) to ... $60.00 per share in cash and 2.2 Mylan ordinary ... The Board previously concluded that Mylan,s unsolicited ... and its future growth prospects and was not in ...
(Date:4/24/2015)... -- Bayer Corporation hosted its annual "Take Your Child to Work ... headquarters.  This is Bayer,s second "Take Your Child To Work ... campus, and Thursday,s event welcomed 230 children ready to see ... Fortunately, for the kids, this was not just another ... "Science For A Better Life," Bayer made sure that "Take ...
(Date:4/24/2015)... , April 24, 2015  IGI Laboratories, Inc. (NYSE ... based specialty generic pharmaceutical company, announced the Company will ... Tuesday, April 28, 2015 to discuss the 1st quarter ... listen to the call by dialing 1-888-346-3479. International participants ... should ask to be joined into the IGI Laboratories, ...
Breaking Medicine Technology:Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4Bayer Hosts "Take Your Child to Work Day" 2Bayer Hosts "Take Your Child to Work Day" 3Bayer Hosts "Take Your Child to Work Day" 4
... Calif., March 31, 2011 NewCardio, Inc., (OTC Bulletin ... developer, announced today that the Company has been invited ... performance study at an upcoming conference entitled "Cardiovascular Safety ... Food and Drug Administration (FDA), the Cardiac Safety Research ...
... 31, 2011 The U.S. Department of Energy has ... field of medical technology and innovation for commercializing the ... agency, Dilon and similar entrepreneurs, "build the new industries ... our toughest global challenges." The Dilon 6800® ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6U.S. Department of Energy Hails Dilon Diagnostics as a Medical Technology Pioneer and Top National Innovator 2
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... The Stryker Cross-Screw System offers ... secure method for ACL reconstruction ... Stryker Cross-Screw System provides the ... The implant comes in Titanium ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
The Stryker Shoulder Instrumentation Set is ideal for open and arthroscopic shoulder procedures. The kit includes all the necessary tools for bone and tissue preparation as well as suture management ...
Medicine Products: